

Appendix – 10A

Undertaking regarding No Objection Certificate from Lending Scheduled Commercial Banks/ Financial Institutions for Composite Scheme of Arrangement and Amalgamation (Merger by Absorption)

To,
Manager - Listing Compliance
National Stock Exchange of India Limited
'Exchange Plaza'. C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400 051

To,
The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001

Dear Sir/ Ma'am,

Re.: Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) under Sections 230 to 232 read with Section 234, Section 52, Section 66 and other applicable provisions of the Indian Companies Act, 2013 and the provisions of Section 210 read with Section 212 and other applicable provisions of the Singapore Companies Act, 1967, amongst Steriscience Specialties Private Limited ("SSPL" or "Transferor Company 1") and Brooks Steriscience Limited ("BSL" or "Transferee Company 1" or "Transferor Company 2") and Steriscience Pte. Limited ("Steriscience SG" or "Transferor Company 3") and Strides Pharma Services Private Limited ("SPSPL" or "Transferor Company 4") and OneSource Specialty Pharma Limited ("OneSource" or "Transferee Company 2") and their respective shareholders (the "Scheme" or "Draft Scheme")

With reference to the proposed Draft Scheme, we hereby confirm that we have initiated the process of obtaining the No Objection Certificate from the lending scheduled commercial banks/financial institutions/debenture trustees as required under Para A (2) (k) of Part I of SEBI Master Circular dated June 20, 2023 and we shall submit the same with the Exchange before the receipt of the No-objection letter from stock exchange in terms of Regulation 37(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For OneSource Specialty Pharma Limited

Trisha A
Company Secretary
ICSI Membership No.: A47635

Date: September 30, 2025